LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
1075
via seekingalpha.comBusiness & Companies

AbbVie releases phase 3 induction therapy data on injectable Skyrizi for Crohn's

FROM THE WIRE · SEEKINGALPHA.COM

AbbVie’s phase 3 AFFIRM data show subcutaneous Skyrizi improved Crohn’s endoscopic remission and ulcer-free rates. Read more here.

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive phase 3 data support Skyrizi's efficacy profile and could strengthen the drug's commercial potential.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Subcutaneous Skyrizi improved endoscopic remission and ulcer-free rates in Crohn's disease.
  2. 02Phase 3 AFFIRM data represent an important milestone in the drug's clinical development.
  3. 03Positive results could support future regulatory approvals and indication expansion.

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.